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Abstract
Glucocorticoids are essential for life, but are also implicated in disease pathogenesis and may produce unwanted effects
when given in high doses. Glucocorticoid receptor (GR) transcriptional activity and clinical outcome have been linked to its
oligomerization state. Although a point mutation within the GR DNA-binding domain (GRdim mutant) has been reported as
crucial for receptor dimerization and DNA binding, this assumption has recently been challenged. Here we have analyzed
the GR oligomerization state in vivo using the number and brightness assay. Our results suggest a complete, reversible, and
DNA-independent ligand-induced model for GR dimerization. We demonstrate that the GRdim forms dimers in vivo whereas
adding another mutation in the ligand-binding domain (I634A) severely compromises homodimer formation. Contrary to
dogma, no correlation between the GR monomeric/dimeric state and transcriptional activity was observed. Finally, the state
of dimerization affected DNA binding only to a subset of GR binding sites. These results have major implications on future
searches for therapeutic glucocorticoids with reduced side effects.
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Introduction
Glucocorticoids influence the activity of almost every cell in
mammalian organisms, mainly through binding to the glucocor-
ticoid receptor (GR). In the absence of ligand GR primarily
localizes in the cytoplasm while the activated GR-ligand complex
is mainly nuclear. Once in the nucleus, the GR regulates gene
expression by directly binding to specific DNA sequences or by the
interaction with, and modulation of other transcription factors [1].
These two main mechanisms of action were historically named
GR transactivation and GR transrepression, respectively [2]. Even
though GR homodimerization is considered an essential step in
the GR-transactivation pathway, it is still not clear whether GR
dimerizes before [3–6] or after [7–9] DNA binding; or which
regions of the protein are functionally involved in the homo-
dimerization process [10]. Nevertheless, as GR transactivation was
originally correlated with side effects of long-term clinical use of
glucocorticoids, intense efforts have been made to design GR
ligands with ‘‘dissociated’’ glucocorticoid properties that exclu-
sively activate the transrepression pathway [11]. Since the current
model of the GR mechanism of action states that the monomeric/
dimeric status of the receptor defines its transcriptional activity,
most of the rational drug design strategies have been focused on
the search for ligands that promote the monomeric (i.e.,
transrepression) form of GR [12].
GR is a modular protein organized into three major domains:
the N-terminal ligand-independent activation function-1 domain;
the central DNA-binding domain (DBD); and the C-terminal
ligand-binding domain (LBD) [13]. Crystal structures of both
DBD [14] and LBD [15] have been obtained separately but no
reports have described a structure of the entire protein. The first
crystal structure of the GR DBD revealed a dimerization region,
and subsequent mutational studies partially defined a five amino
acids sequence, named the D-loop, that could potentially be
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involved in GR dimer formation [8]. However, these earlier
studies were performed with a GR fragment and entirely in vitro.
Following this work, a point mutation within the human GR DBD
(A458T) in the context of the entire protein was reported to be
able to separate transactivation from transrepression and unable to
dimerize [16], although no direct evidence supported the latter
conclusion. The human GRA458T, mouse GRA465T, and rat
GRA477T have been commonly referred to as the ‘‘GRdim’’
mutants [17].
From a transcriptional standpoint, early studies characterized
the GRdim mutant as unable to transactivate genes but able to
transrepress both in vitro [16] and in vivo [18]. However, GRdim’s
inability to transactivate has been challenged after results that
showed this mutant can induce gene expression in a sequence and
context-dependent manner [19–21]. From a biophysical stand-
point, the early GRdim studies established that dimerization was
entirely dependent on the DBD region. However, a recent study
confronted this idea by showing protein-protein interactions
between GRdim molecules [22].
Here we performed in vivo mapping of the GR oligomerization
state by using the number and brightness (N&B) method [23]. We
present conclusive evidence showing dimerization of the GRdim
mutant while an additional mutation in the LBD (I634A) severely
compromises homodimer formation. Importantly, no correlation
between oligomerization state, DNA binding, and transcriptional
activity could be established. These results question a key
paradigm in the quest for glucocorticoid ‘‘dissociated’’ ligands.
Results
Image Analysis Reveals GR Oligomerization State in
Living Cells
To determine the state of GR dimerization in living cells, we
performed the N&B method [23]. This novel technique, based on
moment-analysis, provides the average number of moving
fluorescent molecules and their brightness at every pixel in the
images (Figure 1A and 1B). In the simplest case the brightness of
an oligomer consisting of n monomers is n-times the brightness of
the n-monomers. Therefore, N&B is a useful method to obtain the
oligomerization state of proteins in living cells with high spatial
resolution. Figure 1C shows the nuclear brightness e (i.e., measure
of fluorophore oligomerization) corresponding to the wild-type
enhanced green fluorescent protein (eGFP)-GR expressed in baby
hamster kidney (BHK) cells. As we previously demonstrated [24],
e values significantly increased (approximately 2-fold) in the
nucleus of cells treated with dexamethasone (Dex), consistent with
a virtually complete population of GR dimers upon ligand
addition. eGFP brightness is statistically indistinguishable from
unstimulated eGFP-GR, indicating that nuclear eGFP-GR is
mostly monomeric in the absence of ligand. Similar results were
observed in the presence of the natural ligand corticosterone (Cort)
(Figure 1C). As a negative control, no GR dimer formation was
observed in cells treated with the non-steroidal ligand compound
A (CpdA), in agreement with previous studies [25]. Recently, an in
vitro study reported that the GR exists mostly as a monomer [26].
If that were the case in vivo, we would have detected an average
brightness below two-fold in our system because of a linear-
weighted-average combination from the contribution of the
monomer/dimer population. Nevertheless, we cannot rule out
the existence of a small population of monomeric molecules or
even a small proportion of other oligomers.
Previous reports have suggested that GR dimer formation is an
irreversible process in vitro [26]. Thus, we evaluated the stability of
GR dimers in vivo by performing washout experiments. Interest-
ingly, Cort withdrawal significantly reduced the population of GR
dimers (Figure 1C), even though GR remained in the nucleus
(Figure 1D), demonstrating that dimerization is a reversible
process in vivo. Importantly, Dex washouts did not affect
dimerization most likely due to the high affinity of this ligand for
the receptor [27]. As we previously described [24], in our N&B
assay there is an excess eGFP-GR molecules due to over-
expression in comparison to accessible glucocorticoid response
elements (GREs) at a given time. Moreover, any given GRE is
only transiently bound by GR during physiological transcriptional
activation [28,29]. Hence, the virtually complete population of
dimers observed is more compatible with a DNA-independent
model for GR dimerization.
The GRdim Forms Dimers In Vivo and Binds DNA
Next, we decided to test the oligomerization status of the
GRdim mutant using N&B. Interestingly, treatment of eGFP-
GRA465T expressing cells with Dex showed an increase in nuclear
brightness virtually identical to that observed with the wild-type
receptor (Figure 2A), clearly demonstrating that this mutant is able
to form dimers in vivo. Interestingly, the weaker natural steroid
Cort also induces significant GRA465T dimerization although with
less efficiency than Dex (Figure 2A).
Recently, it has been suggested that GR expression levels affects
the dimerization status of the receptor [30]. Since we were
working in an over-expression system due to the transient
transfection of eGFP-GR, we decided to study GR oligomerization
status in a model expressing physiological levels of the receptor.
We generated mouse embryonic fibroblast (MEF) cell lines from a
GR null mouse stably expressing a mouse eGFP-GR protein at
endogenous levels (Figure S1). N&B analysis of the MEF cell lines
showed that the wild-type GR fully dimerizes in the presence of
Dex and that the GRdim also forms dimers, although with a
slightly less efficiency than the wild-type receptor (Figure 2B).
Nuclear translocation was similar for both the GRwt and the
GRA465T mutant (Figure 2C). In conclusion, both ligand affinity
and GR expression levels have no apparent effect on the
Author Summary
The powerful anti-inflammatory and immunosuppressive
action of glucocorticoids have made them one of the most
prescribed drugsworldwide. Unfortunately, acute or chronic
treatment may have severe side-effects. Glucocorticoids
bind to the glucocorticoid receptor (GR), a ligand-depen-
dent transcription factor. GR regulates gene expression
directly by binding to DNA or indirectly by modulating the
activity of other transcription factors. It is currently accepted
that the direct pathway is mostly responsible for glucocor-
ticoids side-effects and that the oligomerization state of the
GR (whether it is a dimer or a monomer) determines which
pathway (direct or indirect) will prevail. Hence, scientists
have tried to develop ‘‘dissociated ligands’’ able to
specifically activate the GR indirect pathway. In the present
work, we employed a novel microscopy method named the
number and brightness assay, which measures GR oligo-
merization state inside the living cell. Our results suggest
that—contrary to the established view—there is no clear
correlation between the oligomerization state of GR and the
mechanistic pathway the receptor will follow upon ligand
binding. This discovery presents supporting evidence
towards the increasing view of the inherent complexity
of glucocorticoid action and might impact future
approaches towards the design of safer synthetic
glucocorticoids.
A Monomeric Glucocorticoid Receptor Mutant
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Figure 1. The N&B method and its application to GR dimerization. (A) The molecular brightness (e) can be measured by analyzing the frame-
to-frame intensity fluctuations in the confocal volume (,fl). Fluctuations are analyzed by measuring the ratio between the variance of the intensity
signal s2 and the mean intensity value ,I.. When fluorescent molecules are immobile, this ratio describes instrument noise which follows a Poisson
distribution (s2 =,I.). If the signal fluctuates due to mobile molecules, the ratio s2/,I. is directly proportional to the e of the diffusing species. The
scheme illustrates the standard deviation for an equal number of fluorophores organized as immobile monomers (s0), mobile monomers (s1),
A Monomeric Glucocorticoid Receptor Mutant
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dimers (s2), or trimers (s3). Figure adapted from Hellriegel and colleagues [55]. The sampling time (i.e., pixel dwell time) has to be short enough that
the intensity fluctuations are not averaged out (,ms) while the re-sampling time (i.e., frame time) must be longer (,ms-s) to measure independent
fluctuations due to different populations of molecules at the same pixel [23]. (B) To obtain e of a fluorescent protein in living cells, a stack of images is
acquired. Pixels that correspond to a specific region of interest (ROI) can be selected (e.g., the nuclear compartment) and e is calculated for each pixel.
Finally, the average e for that region is obtained by fitting to a Gaussian distribution. (C–D) BHK cells (transfected with pEGFP-GR or pEGFP) were
incubated with vehicle (control), 100 nM dexamethasone (Dex), 100 nM Cort or 10 mM CpdA. Where indicated, ligand was removed by washing and
changing to ligand-free media (washout) as previously described [27,56]. For each cell (n= 273) e was calculated as shown in (B). (C) Fold-increase of
the nuclear brightness (e) relative to the control (monomeric GR). Means 6 SEM are shown. Bars with different superscript letters are significantly
different from each other (p,0.05). (D) Subcelluar distribution in one representative cell for each treatment. Scale bar = 8 mm.
doi:10.1371/journal.pbio.1001813.g001
Figure 2. The GRdim forms dimers and binds DNA in vivo. 3617 cells transiently expressing eGFP-GRwt or eGFP-GRA465T (A), or null GR MEF cell
lines stably expressing eGFP-GRwt or eGFP-GRA465T (B) were treated with vehicle (control), 100 nM Dex, or 100 nM Cort. The fold-increase of the
nuclear brightness (e) relative to the control (total n= 311) is shown. Bars with different superscript letters are significantly different from each other
(p,0.05). (C) Subcelluar distribution of eGFP-GR in representative MEFs cells. Scale bar = 10 mm. (D) GR loading at the MMTV promoter array (white
arrow) in the 3617 cell line (single cell analysis). Scale bar, 4 mm.
doi:10.1371/journal.pbio.1001813.g002
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dimerization status of the wild-type receptor. On the other hand,
the GRdim oligomerization status is mildly sensitive to both ligand
and receptor expression levels.
Another alleged property of the GRdim is its inability to bind
DNA [16,18], although it has also been questioned [19,20,22,31].
To address this, we evaluated in vivo recruitment to DNA in the
3617 mouse cell line, which contains an amplified array of a GR
responsive promoter structure (the mouse mammary tumor virus
[MMTV] array). Thus, eGFP-GR interactions with MMTV
GREs can be directly visualized in living cells as a bright spot [32].
Figure 2D clearly shows array formation on both GRwt and
GRA465T receptors. In summary, the GRdim seems to be able to
dimerize and to bind DNA in vivo.
Could the Dimeric GR also Be Responsible for
Transrepression?
The transcription factor NF-kB mediates key inflammatory
pathways and its interaction with GR has been widely document-
ed [1]. NF-kB is mainly composed of the heterodimer p50/p65,
although p65 homodimers have also been described [33]. The
transrepression hypothesis sustains that the GR interacts with p65
exclusively as a monomer; however, this idea relies almost entirely
on the GRdim paradigm. The fact that monomeric GR molecules
like CpdA-GR complexes are able to transrepress [34] does not
rule out the possibility that GR dimers would also be capable of
transrepression. To test this, we assessed the ‘‘dimeric transrepres-
sion’’ hypothesis by analyzing the oligomerization state of
mCherry-GR in the presence of GFP-p65. Figure 3A shows
N&B analysis of cells expressing mCherry or mCherryGR in the
presence or absence of GPFp65, and Figure 3B contains
representative images of these cells. As expected, in the presence
of ligand mCherryGR showed full GR dimerization (Figure 3A). If
GR interacts with p65 as a monomer, then GFP-p65 presence
should decrease the population of mCherryGR dimers. However,
no effect on mCherryGR oligomerization state is observed when
GFP-p65 is present (Figure 3A). Brightness analysis also confirms
that GFP-p65 dimerizes upon TNF addition. Moreover, this
dimerization state was maintained in the nucleus containing Cort-
activated GR molecules. To evaluate mCherryGR and GFP-p65
interactions, cross correlation analysis of the intensity fluctuations
[35] was performed on the same data set. When untagged GFP
and mCherry particles were analyzed, a symmetric cross
correlation (brightness cross correlation [Bcc]) centered on zero
was observed (Figure 3C), indicating an absence of interaction
between the GFP-mCherry pair. On the contrary, mCherryGR
and GFP-p65 showed an asymmetric, positive Bcc value
(Figure 3C), indicating an interaction between GR and p65
molecules under our experimental conditions. Overall, although
we cannot directly measure the stoichiometry of the GR-p65
complex, the most parsimonious model that fits our data is the one
where Cort-stimulated GR is interacting with p65 as a dimer.
Multiple Domains Are Involved in GR Dimerization
As demonstrated above, GRdim is able to form dimers in vivo
(Figure 2). If the DBD dimerization surface is indeed compromised
in the GRdim mutant, then another region of the protein must
participate in GR-GR interactions. An interesting candidate is the
LBD region, where a second dimerization surface has been
described [15] but whose functional relevance has been questioned
on the basis of studies performed with DBD mutants like GRdim
[10,36]. According to the GR LBD/Dex crystal structure, the
dimerization interface includes a central hydrophobic region made
up of reciprocal interactions between residues in the bA strand and
a network of hydrogen bonds involving residues of the H1–H3
loop [37]. In a previous report, we characterized a rigid steroid
ligand, 21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP),
which behaves as a GR agonist in transrepression assays but as
an antagonist in transactivation ones [24]. According to molecular
dynamics (MD) simulations, 21OH-6,19OP induces a dramatic
change in the average position of the H1–H3 loop within GR’s
LBD [38]. N&B studies showed that 21OH-6,19OP is still able to
induce GR dimerization (Figure 4A and [24]), which suggests that
GR-21OH-6,19OP complexes dimerize through the DBD dimer-
ization surface since the H1–H3 loop is compromised. Consistent
with this hypothesis, GRA465T dimerization was abrogated in cells
treated with 21OH-6,19OP (Figure 4B), even though this
compound induced GR nuclear translocation (Figure 4B, right
panel). Together, these results suggest that GR form dimers in vivo
through the combined action of the LBD and the DBD regions.
This model explains how the MD predictions performed on the
GR-21OH-6,19OP complex are only detected in vivo when the
DBD is compromised (i.e., in cells expressing GRA465T).
The GRmon: A Monomeric Glucocorticoid Receptor
To further evaluate the functional contribution of the DBD and
LBD regions on GR dimerization, we constructed the mutant
eGFP-GRI634A, on the basis of the orthologous human mutation
I628A (residue localized at the bA strand) previously reported to
decrease by 10-fold the dimerization of LBD-LBD fragments in
vitro [15]. Figure 4C shows that eGFP-GRI634A has a diminished
ability to form dimers in the presence of 0.1 mM Dex, although its
subcelluar localization remains nuclear (Figure 4C, right panel).
Activation of the receptor with 1 mM Dex slightly increases
dimerization, supporting a previous report suggesting that the
human I628A may have reduced affinity for Dex [15]. Interest-
ingly, when we combined the mutations in the DBD and the LBD
dimerization surface (eGFP-GRA465T/I634A) dimer formation was
completely abolished with 0.1 mM Dex and severely compromised
in the presence of 1 mM Dex (Figure 4D), suggesting a
combinatorial contribution of both domains on GR dimerization.
Similar behavior of these mutants was observed in both 3617 cells
and in the MEF cell line with low-expression levels of GR (Figure
S2). Accordingly, we named the GRA465T/I634A mutant GRmon as
it is defective in dimerization in vivo. Consistent with the N&B data,
the Fo¨rster resonance energy transfer (FRET) assay also indicated
that the GRmon is impaired in dimerization (Figures 4E, 4F, and
S3).
We next characterized the transcriptional activities of all GR
mutants. In agreement with previous data [16] luciferase reporter
assays showed that GRA465T has little transactivation activity
(Figure 5A) but similar transrepression efficiency (Figure 5B)
compared to the wild-type receptor. As originally reported [15],
GRI634A also promotes poor transactivation activity (Figure 5A);
however, transrepression of an NF-kB reporter was not affected
(Figure 5B). The GRmon behaves similarly to the single DBD and
LBD point mutants (Figure 5). Consistently, transcriptional
activation of endogenous genes in the eGFPGR-MEFs cell lines
showed a similar trend (Figure 5C).Taken together, our results
show no correlation between the dimeric/monomeric state of the
receptor and its ability to transactivate or transrepress gene
expression, at least in the context of reporter gene assays.
GR Recruitment to GREs: De Novo Versus Pre-
programmed Sites
We next analyzed the ability of the LBD mutants to bind to the
MMTV array in 3617 cells. Similar to the GRwt and GRA465T
(Figure 2D), array formation was successfully observed upon Dex
addition with GRI634A (Figure 6A, white arrows). On the contrary,
A Monomeric Glucocorticoid Receptor Mutant
PLOS Biology | www.plosbiology.org 5 March 2014 | Volume 12 | Issue 3 | e1001813
although a few cells were positively visualized (unpublished data),
we failed to observe a considerable number of cells with arrays in
the presence of GRmon (Figure 6A). To confirm these results with
an average-population, quantitative approach, we performed
chromatin immunoprecipitation (ChIP) assays using a GFP
antibody on the MMTV array. In agreement with the imaging
data, all single GR mutants can occupy the MMTV region but
GRmon is poorly recruited (Figure 6B). Interestingly, both
GRA465T and GRI634A are able to bind DNA with less efficiency
than their wild-type counterpart (Figure 6B). The eGFP-GR
mutants in ChIP experiments were expressed at a similar level
(Figure S4).
The recruitment of transcription factors to chromatin depends
on a variety of complex events. An emerging paradigm suggests
that the local chromatin structure of response elements contributes
strongly to the tissue-specific action of many transcription factors
[39]. In particular, in vivo GR recruitment to DNA is strongly
dependent on the chromatin landscape, with most of the GR
binding events occurring at pre-programmed chromatin (i.e.,
DNaseI hypersensitive sites prior to ligand treatment) and only a
Figure 3. GR does not change its oligomerization state in the presence of NF-kB. 3617 cells transiently expressing the indicated
combination of mCherry, mCherryGRwt, GFP, and/or GFP-P65 were treated with 300 nM Cort and/or 10 ng/ml TNF-a (TNF). (A) Fold-increase of the
nuclear brightness (e) relative to the control (total n= 215) for the green or red channels (color coded). Parenthesis means ‘‘in the presence of.’’ Bars
with different superscript letters are significantly different from each other (p,0.05). (B) subcelluar distribution of eGFP of mCherry in one
representative cell for each condition. Scale bar = 10 mm. (C–D) Cross correlation analysis of the fluorescence fluctuations. The cross correlation
brightness (Bcc) plot for each pixel (blue dots) of a representative nucleus as defined in Digman and colleagues [35] as well as a histogram of the Bcc
are shown.
doi:10.1371/journal.pbio.1001813.g003
A Monomeric Glucocorticoid Receptor Mutant
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Figure 4. The GRmon is severely impaired in dimerization. (A–D) N&B assay. BHK cells (transfected with the indicated pEGFP-GR mutants)
were treated with vehicle (control), Dex, or 10 mM 21-hydroxy-6,19-epoxyprogesterone (21-OH). The fold-increase of the nuclear brightness (e)
relative to the control (total n= 659) and the subcelluar distribution of eGFP-GR in one representative cell for each treatment are shown. Scale
bar = 8 mm. (E–F) FLIM-FRET analysis. 3617 cells transiently transfected with the indicated plasmids were treated with 100 nM Cort for 30 min and
fixed. The lifetime of EGFP was measured as described in the ‘‘Materials and Methods’’ section. The mean FRET efficiency for the sREACh-EGFP pairs 6
SEM (n=25–26 cells per group) (E) and representative cells (F) are shown; with pseudo-color-coded lifetime images scaled from 0.5–2.5 ns where
warmer colors represent shorter liftetime values (top row) and the corresponding fluorescence intensity images (bottom row). Scale bar = 10 mm.
Distribution frequencies of lifetime maps are additionally presented in Figure S3.
doi:10.1371/journal.pbio.1001813.g004
A Monomeric Glucocorticoid Receptor Mutant
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small fraction of binding at de novo sites (i.e., DNaseI sites actively
induced by the receptor) [40]. To further characterize the GR
mutants, we performed ChIP assays on a few pre-programmed or
de novo sites. Irrespective of the sites analyzed, both the GRA465T
and the GRI634A were able to bind chromatin (Figure 6C and 6D),
although their relative occupancy compared to the wild-type was
site-specific. Interestingly, GRmon was recruited to most of the
pre-programmed sites evaluated (Figure 6D) while no significant
binding was observed to de novo sites (Figure 6C). Finally, we
evaluated GR recruitment to recently reported negative GREs
(nGREs) [41], which were suggested to be preferential binding
sites of the monomeric GR [9]. To identify nGREs in 3134 cells,
we overlapped all 1,147 putative nGREs conserved between
human and mouse [41] with GR ChIP-seq data from 3134 cells
[40]. Surprisingly, only five were found at GR binding sites in
3134 cells (Figure S5). From these, three were located near Dex-
repressed genes as shown by microarray analysis [42]. ChIP results
show no clear link between the mutants and the receptor’s ability
to bind nGREs (Figure 6E). In summary, our data suggest that the
dimeric status of the receptor neither defines its transactivation
activity nor predicts its ability to bind chromatin in vivo. On the
other hand, the monomeric form of GR seems to be less efficient
in its ability to bind chromatin than the dimeric form of the
receptor.
Discussion
Studies mainly using the GRdim mutant suggested the
dissociated model of GR action and led to the transrepression
hypothesis [2]. This hypothesis states that suppression of
inflammation by GR is mainly mediated by the transrepression
mechanism, and is independent of GR transcriptional regulation
through its direct binding to DNA. Accordingly, side effects of
glucocorticoids were suggested to be dependent on GR dimeriza-
tion, GR-GRE interaction, and the downstream consequence on
gene regulation. This model has been the guiding principle in the
search of new compounds with dissociated glucocorticoid proper-
ties [11]. Today this strategy is deeply criticized, not only because
it is known that some glucocorticoid anti-inflammatory effects
depend on gene activation [2,43], but also because evidence
against GRdim’s alleged monomeric status and inability to bind
DNA is accumulating [19,20,22,31]. Here, we demonstrate that
the so-called GRdim is able to dimerize in vivo while the new
mutant GRmon (A465T/I634A) is severely impaired in dimer
Figure 5. Transcriptional activity of the GR mutants. (A–B) Cos-7 cells were co-transfected with pEGFP-GR vectors and the MMTV-Luciferase
reporter vector (A) or pkB-Luciferase reporter and pRelA expression vectors (B). Cells were incubated in the presence or absence of 100 nM Dex and
luciferase activity was measured. (A) Values (induction efficiency) were expressed as percentage activity relative to Dex-treated wild-type GR. (B)
Values (GR’s inhibition efficiency on NF-kB activity) were expressed as percent induction relative to the control. (C) Nascent mRNA levels on MEFs cell
lines stably expressing the GFPGR mutants. Means 6 SEM from three independent experiments are shown. Bars with different superscript letters are
significantly different from each other (p,0.05).
doi:10.1371/journal.pbio.1001813.g005
A Monomeric Glucocorticoid Receptor Mutant
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Figure 6. DNA binding and chromatin recruitment of the GR mutants. (A) GR loading at the MMTV promoter array (white arrow) in the 3617
cell line (single cell analysis). Scale bar, 4 mm. (B–E) ChIPs using a GFP antibody in the 3134 cell line previously transfected with pEGFP-GR mutants.
qPCR data as ChIP pulldown/input normalized to vehicle-treated cells (n= 4) for the MMTV promoter array (B) or endogenous GR binding sites, either
de novo (C), pre-programmed (D), or nGRE (E). Means6 SEM from four independent experiments are shown. Bars with different superscript letters are
significantly different from each other (p,0.05). If at least one superscript letter is shared between treatments, then no significant differences were
found.
doi:10.1371/journal.pbio.1001813.g006
A Monomeric Glucocorticoid Receptor Mutant
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formation. We have studied the oligomerization state of GR by the
novel N&B technique, under both physiological and over-
expressed GR levels. Independent confirmation that the GRmon
is impaired in dimerization has been obtained by fluorescence
lifetime imaging microscopy (FLIM)-FRET analysis.
If the GRdim is still able to bind DNA and form dimers as
demonstrated here and elsewhere [19,20,22,31], why is this mutant
unable to transactivate genes? Recent studies have shown that the
GRdim’s residence time on DNA is ten times less than the one
observed for wild-type GR [29], in strict agreement with its
diminished transcriptional activity according to the ‘‘hit and run’’
model of transcriptional activation [44,45]. Also, it has been shown
in vitro that the dim mutation alters the allosteric effect that DNA
exerts on GR, therefore varying the receptor’s conformational states
and perhaps changing the ability to interact with co-regulators [20].
Even though it has not been directly tested, GRdim’s altered ability
to interact with specific cofactors could explain why this mutant is
able to induce the expression of genes whose promoters contain
certain GREs and not others [19–21]. In other words, the dim
mutation does not actually appear to abolish GR transactivation
altogether but instead their effect depends on both gene and cellular
context, producing an overall change in the whole transcriptional
outcome. As an example, a microarray analysis performed in U-2
OS cells showed a very different pattern of gene regulation
comparing wild-type and GRdim expressing cells [22]. Moreover,
expression analysis performed in livers from wild-type and dimmice
revealed that GRdim could induce gene expression when compared
with wild-type GR [46]. Overall, there is compelling evidence that
suggests that the transactivation versus transrepression model that
arouse from the GRdim mouse phenotype was oversimplified and
needs re-examination [2,43]. More genome-wide studies on the dim
model will provide much needed insights in the mechanisms
underlying the GRdim mice phenotype.
The establishment in the community that transactivation is
mediated by GR dimers and transrepression occurs exclusively
through GR monomers has been built almost entirely under the
GRdim paradigm [16,18,47]. However, here we find no
correlation between the dimeric/monomeric state of the receptor
and its ability to transactivate or transrepress reporter genes. For
example, even though GRwt and GRdim are mainly dimeric the
latter is severely impaired in transactivation compared to the wild-
type GR. On the other hand, the GRmon is mainly monomeric
but its transrepression efficiency is indistinguishable from the fully
dimeric wild-type receptor. Hence, changing the relative popula-
tion between dimers and monomers does not necessarily change
the transcriptional outcome. In conclusion, GR dimerization
appears necessary but not sufficient for transactivation and it is not
required for transrepression. Nonetheless, given the fact that GR
transcriptional activity is highly gene- and cell type- specific more
studies are needed to properly evaluate the scope of this
conclusion. Interestingly, our data suggest that Cort-GR molecules
remain dimeric in the presence of GR/NF-kB interactions. Thus,
the idea that transactivation could be dissociated from transre-
pression through manipulation of the oligomerization state of the
receptor should be critically revised, if not entirely discarded.
Overall, our results indicate that GR dimerization involves a
more complex mechanism than previously anticipated. Moreover,
we also challenge the view that transrepression is exclusively
performed by the monomeric GR. This implies that the simplified
monomer/dimer model equilibrium does not explain GR
transactivation versus transrepression activity. It seems that the
prevailing view was established without rigorous verification and
new approaches for mitigating the side effects of chronic
glucocorticoid treatment should be explored.
Materials and Methods
GR Ligands
Dex and Cort were purchased from Sigma-Aldrich. CpdA [25]
was purchased from Enzo Life Sciences. 21OH-6,19OP was
prepared as previously described [48].
Plasmids Constructs
pEGFP-GR expresses the eGFP protein fused to the N-terminal
end of the mouse GR [24]. pEGFP-GRA465T was generated by
site-directed mutagenesis by TOP Gene Technologies. pEGFP-
GRI634A and pEGFP-GRA465T/I634A were generated by site-
directed mutagenesis by Stony Brook cloning facility (Stony Brook
University, New York, USA). mCherry-GR was previously
described [49]. For FLIM-FRET experiments, the coding region
of the super (s)REACh fluorophore [50] was subcloned into the N-
terminal of the mouse GR sequence (psREACh-GR). Briefly, the
AgeI-BglII eGFP containing sequence of pEGFP-GR and pEGFP-
GRA465T/I634A was replaced with sREACh cDNA PCR amplified
from mGFP-10-sREACh-N3 (Addgene, plasmid 21947) using the
Herculase II fusion DNA polymerase system (Agilent Technolo-
gies). The reverse primer contained an additional five bases,
introducing 59-TACTC-39 into the plasmid prior to the BglII
restriction site and so preserving the same linker as the eGFP
variants.
pMMTV-luciferase; pkB-luciferase, pRelA and pCMV-LacZ
were previously described [24]. GFP-p65 was a kind gift from
Alessandra Agresti [51]. The SV40T-expressing retroviral pBabe-
largeT cDNA and the retroviral pWZL-neo plasmids were a gift
from Kai Ge [52]. The coding region of the eGFP-GR mutants
was cloned into the pWZL-neo vectors for retroviral transduction.
Briefly, each eGFP-GR coding sequence was independently
isolated by PCR (using the high fidelity Herculase II polymerase)
with primers carrying BamHI and MfeI restriction sites:
forward (For) atatggatccGTGAACCGTCAGATCCGCTAG
and reverse (Rev) atcgCAATTGGGCAGCCTTTCTTAG-
TAAGGCAG. The purified fragment was subcloned into
BamHI/MfeI sites of the pWZL-neo vector.
Cell Culture
BHK21 and Cos-7 cells were cultured in DMEM (Invitrogen)
supplemented with 10% FBS (Internegocios S.A.). 3134 and 3617
cells were cultured in DMEM and supplemented with 10% FBS
(Hyclone). The 3134 cell line is a mouse mammary adenocarci-
noma cell line. It contains a large tandem array (,200 copies) of a
mouse mammary tumor virus, Harvey viral ras (MMTV-v-Ha-ras)
reporter. The 3617 cell line is a derivative of 3134 cell line
expressing a GFP-tagged version of GR (GFP-GR) from a
chromosomal locus under control of the tetracycline repressible
promoter. Both cell lines were described previously [53]. In all
cases, prior to glucocorticoid treatment cells were incubated at
least 18 h in DMEM medium containing 10% charcoal-stripped
FBS (Hyclone).
GFP-GR Mutants-MEFs Cell Line
Heterozygous GR-deficient (GR het) mice were generated by
crossing mice with one allele of GR exon 3 flanked by loxp sites
[54] with mice expressing Cre driven by the b-actin promoter.
Day 13.5 embryo bodies from a timed GR het6GR het mating
were minced with scissors and forceps, digested with trypsin, and
cultured in DMEM supplemented with FCS and glutamine at
37uC in 5% CO2. GR-deficient MEFs were identified by PCR as
being positive for the deleted allele and negative for the germline
allele. Primary fibroblasts were immortalized via retroviral
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transduction with SV40 large T antigen. Briefly, 5 million Phoenix
A cells were plated in a 10-cm dish 24 hours prior to transfection
with 10 mg pBabe-SV40 (Puro) plasmid using JetPRIME trans-
fection reagent (Polyplus transfection) according to the manufac-
turer’s recommended protocol. Virus containing supernatant was
collected 48 hours post-transfection and filtered through a
0.45 mM filter. Filtered virus-containing Phoenix cell supernatant
was diluted with an equal volume of fresh media and polybrene
was added to a final concentration of 5 mg/ml. 2 ml of this virus
solution was used to infect 200,000 MEFs. 48 hours post-
transduction the cells were challenged with 2 mg/ml puromycin
(SIGMA-Aldrich). Puromycin selection was complete in 3–4 days,
however these large T antigen immortalized MEFs were
maintained in media containing 2 mg/ml puro. The immortalized
MEF cell lines (wt and GR2/2) were transduced with pWZL-
GFPGR (Neo) as described above. These cells were selected with
500 mg/ml G418 (Cellgro). After 15 days of Neomycin selection,
cells were sorted by FACS according to their GFP expression into
three categories (low, medium, high). eGFP-GR levels were
monitored by Western blot (Figure S1) and medium expression
cells were chosen for further studies.
Transient Transfections
BHK21 and Cos-7 cells were transiently transfected with
Lipofectin 2000 (Invitrogen) according to manufacturer’s instruc-
tions. 3134 and 3617 cells were transfected with jetPRIME
reagent (VWR) according to manufacturer’s instructions.
Subcellular Localization and N&B Analysis
36105 BHK cells were transfected with 1.5 mg of pEGFP-GR
or the mutant variants and incubated with vehicle, 100 nM Dex,
1 mM Dex, 100 nM Cort, 10 mM 21OH-6,19OP, or 10 mM
CpdA for at least 1 h. Washout procedures consisted in washing
the cells three times with pre-warmed (37uC) PBS and then adding
hormone-free media for 20–40 minutes before analysis. Measure-
ments were done in a FV1000 confocal laser scanning microscope
(Olympus), with an Olympus UPlanSApo 606 oil immersion
objective (NA=1.35). The excitation source was a multi-line Ar
laser tuned at 488 nm (average power at the sample, 700 nW).
Fluorescence was detected with a photomultiplier set in the pseudo
photon-counting detection mode.
3617 cells were grown in the presence of 5 mg/ml tetracycline
(Sigma-Aldrich) to inhibit the stable GFP-GR gene expression
[27,53], and transiently transfected with 1.5 mg of pEGFP-GR or
the mutant variants, or a combination of mCherryGR and GFP-
p65 as indicated. Cells were incubated for at least 30 min with
100 nM Dex, 100 nM Cort, or 300 nM Cort in the presence or
absence of 10 ng/ml TNFa (Sigma-Aldrich). Measurements were
done in a LSM 780 laser scanning microscope (Carl Zeiss, Inc.) at
the CCR Confocal Microscopy Core Facility (NIH, Bethesda,
Maryland, USA). We used a 636 oil immersion objective
(NA=1.4). The excitation source was a multi-line Ar laser tuned
at 488 nm and or a 594 nm laser. Fluorescence was detected with
a GaAsP detector in photon-counting mode.
N&B measurements were done as previously described [23]
with some modifications [24]. Briefly, for each studied cell a stack
of 150–200 images (2566256 pixels) were taken in the conditions
mentioned above, setting the pixel size to 80–82 nm and the pixel
dwell time to 6.3 or 10 ms. Each stack was further analyzed using
the N&B routine of the ‘‘GLOBALS for Images’’ program
developed at the Laboratory for Fluorescence Dynamics (UCI,
Irvine, California, USA). In this routine, the average fluorescence
intensity (,I.) and its variance (s2) at each pixel of an image are
determined from the intensity values obtained at the given pixel
along the images stack. The apparent brightness (B) is then
calculated as the ratio of s2 to ,I. while the apparent number of
moving particles (N) corresponds to the ratio of ,I. to B. In a
previous work it has been demonstrated that B is equal to the real
brightness e of the particles plus one [23]. Therefore, e at every
pixel of images can be easily extracted from B measurements.
Importantly, this analysis only provides information regarding the
moving or fluctuating fluorescent molecules since fixed molecules
will give B values equal to 1.
Transactivation and Transrepression Assays
For the transactivation assay, 36105 Cos-7 cells were co-
transfected with 1.5 mg pMMTV-luciferase vector and 0.5 mg of
pEGFP-GR vectors. For the NF-kB transrepression assay, 1.5 mg
pkB-luciferase and 1.5 mg pRelA were used. In all cases, 0.5 mg
pCMV-LacZ was added as transfection control. After transfection,
cells were incubated in DMEM containing 5% charcoal-stripped
FBS and incubated with 100 nM Dex for at least 18 h. Luciferase
activity and b-galactosidase activity was measured as previously
described [24].
Fluorescence Lifetime Imaging Microscopy: Fo¨rster
Resonance Energy Transfer
3617 cells were seeded to 22622 mm glass coverslips in six-well
tissue culture plates. Media contained 10% charcoal-stripped
serum and tetracycline (5 mg/ml) to prevent GFP-GR expression.
Next day cells were transiently transfected with 2 mg total plasmid
using JetPRIME (VWR) and the manufacturer’s protocol. EGFP
(donor) and sREACh (acceptor) plasmids were transfected at 1:2
ratio to maximize the chances of seeing an interaction by FRET.
24 h after transfection cells were treated for 30 min with 100 nM
Cort and fixed in paraformaldehyde added to media (4% final
concentration) for 15 min. Coverslips were washed 36 in PBS and
mounted to microscope slides with Mowiol 4–88 containing 1 mg/
ml p-phenylenediamine as anti-fade (both Sigma-Aldrich). Images
were acquired on a Leica DMI 6000 SP5 inverted confocal
microscope with a 636 oil immersion objective of NA 1.4 (Leica
Microsystems). EGFP excitation at 850 nm was achieved with a
femtosecond mode-locked (80 MHz repetition rate) Mai-Tai HP
pulsed, multi photon laser (Spectra Physics). Fluorescence was
collected using a HPM100 Hybrid Detector R3809U-50 (Becker &
Hickl; Hamamatsu Photonics) through a band-pass GFP filter at
ET 525/50 (Chroma Technology Corp). Fluorescence decays
were resolved by time-correlated single-photon counting (TCSPC)
using a SPC830 acquisition board (Becker & Hickl). Images were
acquired in 2566256 pixel format collecting at least 1,000 photons
per pixel over 2–5 min. Fluorescence transients were acquired
with SPCImage software (Becker & Hickl), analyzed according to
single-life time decay, then exported to Image J (NIH). An in-
house Image J protocol permitted selection of the relevant pixels
(nucleus) and derivation of histograms for the weighted mean
average of the fluorescent lifetimes. These were plotted as
frequency distributions normalized and integrated for area under
the curve using Igor Pro (WaveMetrics Inc). The weighted mean
lifetime (T) was extracted from histograms of individual cells in
Image J and converted to FRET efficiency relative to the GFP-GR
control according to: FRET Efficiency (%) = 12(Tdonor/Tdo-
nor+acceptor)2100 to allow statistical analysis.
Chromatin Immunoprecipitation
3134 cells were seeded in 150 mm tissue culture plates and the
next day transiently transfected with 10 mg of pEGFP-GR or the
mutant variants. Cells were collected the next day after 1 h of
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100 nM dex treatment. ChIP was performed according to the
standard protocol (Upstate Biotechnology) with a crosslinking step
(1% formaldehyde at RT), followed by a quenching step with
125 mM glycine. Chromatin was sonicated by using the Bioruptor
sonicator (Diagenode) with 15 s ‘‘on’’ and 15 s ‘‘off’’ for 30 cycles.
Sonication efficiency was monitored by 2% agarose gel electro-
phoresis. Sonicated chromatin (400 mg) was immunoprecipitated
with an antibody against GFP (Abcam ab290). DNA isolated from
immunoprecipitates, as well as input DNA, was used as a template
for real-time PCR (qPCR). Primers used for qPCR are (59R39):
MMTV, For TGGTTACAAACTGTTCTTAAAACGAGGAT-
G and Rev CTCAGATCAGAACCTTTGATACCAAACC;
LCN2, For TCACCCTGTGCCAGGACCAA and Rev
TGGGGAAGGGTGAGCAAGCT; GluL, For CACTTGGG-
CAAACATGGACGGT and Rev CACAAGAGGAAATGC-
CCCCCT; Mt2, For CATAGCCAGGGCAGCCACAGAA and
Rev GGCAATGCCTTCTTGACTCATTCC; SGK, For
CACTTGGGCAAACATGGACGGT and Rev CACAAGAG-
GAAATGCCCCCCT; Mt1, For TAGGGACATGATGTTC-
CACACGTC and Rev TTTTCGGGCGGAGTGCAGAG;
Tgm2, For CCACACATTGGTTTTGCTATGCTTG and Rev
AATCATTTTCTCATTCCACACAGCC; Ampd3, For GCCA-
GGACGTGGTGTTCAGGAT and Rev GGGCTGGAAA-
TTCTCCTGCG; Sarc, For CCTCAGTCAGTGCTCA-
GTGG and Rev GGGACCAGATGGGATATCAG; Aebp1,
For CTCTTATGCAATCGTTGTCAGTAAATCT and Rev
ATGATGAATGGTGCCTTACAGTCTC; Mocs1, For ATTT-
GGCAGAGACTAGCCTGGAAATGAT and Rev CATCT-
TATGACCTACTTCCACCCCA; S100a4, For ATGGGGTAA-
GGAGCGGAAGG and Rev CTGGACCCAGCCATGCCCTC.
Standard curves were created by 4-fold serial dilution of an input
template. The data presented are from four independent
experiments.
Reverse Transcriptase-qPCR
The MEFs cell lines were plated for 48 h in DMEM medium
containing 10% charcoal-stripped FBS and then treated for 1 h
with 100 nM Dex. RNA extraction was performed with the
Nucleospin RNA-kit (Clontech) according to manufacturer’s
instructions. cDNA was made with the iScript cDNA Synthesis
Kit (Bio-Rad Laboratories, Inc.) from 1 mg RNA. Upon dilution,
cDNA was subjected to qPCR using the iQ SYBR green supermix
(Bio-Rad) with the indicated primers. Primer sequences were
designed to amplify only nascent RNA, using PCR amplicons that
cross an exon/intron or UTR/intron boundary. Primer sequences
are as follows: Mt1, For CCTCACTTACTCCGTAGCTC-
CAGC and Rev TCCCGCCAAGCCTCTACAACTC; Mt2,
For GAACTCTTCAAACCGATCTCTCGTC and Rev TCC-
CAGAAATCCCGTCAGCA; SGK, For GGGAATGGTAGC-
GATTCTCATCG and Rev CGACGCCACACGCTAATCTG;
Actin, For AGTGTGACGTTGACATCCGTA and Rev GCCA-
GAGCAGTAATCTCCTTCT.
Western Blot Analyses
Chromatin samples from ChIPs experiments (i.e., inputs) were
separated by SDS–PAGE and transferred to PVDF membranes.
Blots were probed with primary antibodies anti-GR (sc-1004;
1:1,000), anti-actin (sc-1615; 1:1,000) (Santa Cruz Biotechnology),
or anti-GAPDH (Abcam, ab-8245, 1:1,000) in Tris-buffered saline
(TBS) containing 5% nonfat dry milk, followed by incubation with
horseradish peroxidase (HRP)-conjugated anti-goat, anti-mouse,
or anti-rabbit antibody (Santa Cruz Biotechnology). All blots were
visualized with the ECL kit (Supersignal).
Statistical Analysis
Results were expressed as means 6 SEM. Statistical analyses
were performed with STATISTICA 7.0 (StatSoft, Inc.) and
consisted of one-way ANOVA followed by Tukey’s multiple
comparisons tests. Differences were regarded as significant at p,
0.05 (bars with different superscript letters are significantly
different from each other). Before statistical analysis, data were
tested for homoscedasticity using Bartlett’s test. In some cases,
transformation of the variable (x9= !x) were necessary.
Supporting Information
Figure S1 Generation and characterization of the MEFs
cell lines. MEF cells were obtained from GR null mice (A) and
immortalized by transduction with a retrovirus expressing the
SV40 large T antigen (B). Next, the established MEF GR knock-
out cell line was transduced with the eGFP-GR mutants and
selected for Neomycin resistance (C). Finally, each cell line was
sorted by FACS according to their GFP levels (D). The ‘‘medium’’
expression showed similar eGFP-GR levels to the endogenous GR
in wild-type MEFs (E). Thus, these cell lines were chosen for all
further experiments. Western blot analysis during the entire MEF
generation procedure is shown. For more detail please see the
‘‘Materials and Methods’’ section.
(TIF)
Figure S2 Number and brightness assay on 3617 and
MEF cells. 3617 cells transiently expressing the eGFP-GR
mutants (A), or null GR MEF cell lines stably expressing the
eGFP-GR mutants (B) were treated with vehicle (control), 100 nM
Dex, or 100 nM Cort. The fold-increase of the nuclear brightness
(e) relative to the control (total n=277 for 3617 cells and n=164
for the MEF cells) is shown. Bars with different superscript letters
are significantly different from each other (p,0.05). (C) Subcelluar
distribution of eGFP-GR in representative MEF cells (C). Scale
bar = 10 mm.
(TIF)
Figure S3 FLIM-FRET analysis on GRwt and GRmon.
3617 cells were transiently transfected with the indicated
combination of plasmids and treated for 30 min with 100 nM
Cort. Frequency distribution for the eGFP photon lifetimes with
different donor-acceptor combinations (n=25–26 cells per condi-
tion) is shown. The constructs are identical aside from the
indicated mutations in GR and the fluorophore tag. eGFP-GRwt/
sREACh-GRwt shifts to reduced lifetimes values relative to the
control (no FRET) indicating interaction of the alternatively
tagged GRwt proteins. In contrast, the higher lifetime values for
eGFP-GRmon/sREACh-GRmon indicate impaired interaction
examined by FRET. The binomial distribution of lifetimes in the
eGFP-GRwt/sREACh-GRwt pairing could be due to different
FRET efficiencies produced by varied transient transfection of
donor to acceptor across the cell population.
(TIF)
Figure S4 eGFP-GR protein levels in ChIPs experi-
ments. Chromatin extracts (inputs) from ChIP experiments in
Figure 3 were subjected to Western blot analysis in order to
monitor expression levels between the different eGFP-GR
variants. (A) Representative Western blot using an anti-GR or
anti-actin antibody. (B) Normalized eGFP-GR levels (mean 6 SD)
from four independent experiments.
(TIF)
Figure S5 Searching for nGRE in 3134 cells. (A) Venn
diagram generated by overlapping all putative nGREs conserved
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between human and mouse (taken from Surjit et al., Table S1 [34])
with GR ChIP-seq data (taken from John et al. [33]). (B) The table
shows the genome localization (mm9) of each nGRE found (named
after the nearby gene). We also show the relative expression
according to previously published microarray data [35]. (C) Genome
browser shots of the nGREs from GR ChIP-seq data [33].
(TIF)
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